Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1773230 | 0.93 | HTR2C (0.48) | HTR2CACMSDPSMB5ALDH1A1MAPK1 | |
| SCHEMBL9343204 | 0.91 | HTR2C (0.47) | HTR2CACMSDKCNH2HRH3PSMB5 | |
| SCHEMBL1042357 | 0.82 | HTR2C (0.56) | HTR2CALDH1A1MAPK1CYP2A6HPGD | |
| SCHEMBL10793933 | 0.79 | ACMSD (0.53) | ACMSDKCNH2HRH3PSMB5ALDH1A1 | |
| SCHEMBL968176 | 0.77 | CHRNB4 (0.46) | ACMSDPSMB5ALDH1A1HPGD | |
| SCHEMBL6757113 | 0.76 | ACMSD (0.53) | ACMSDKCNH2HRH3ALDH1A1HDAC1 | |
| SCHEMBL6344544 | 0.76 | ACMSD (0.49) | HTR2CACMSDKCNH2HRH3ALDH1A1 | |
| SCHEMBL362370 | 0.76 | ACMSD (0.44) | ACMSDKCNH2HRH3HDAC1HDAC2 | |
| SCHEMBL2329788 | 0.76 | ACMSD (0.44) | ACMSDKCNH2HRH3PSMB5HDAC1 | |
| SCHEMBL10669275 | 0.76 | CYP3A4 (0.46) | ACMSDKCNH2HRH3ALDH1A1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108191601-B | Synthetic method of 4-cyclopentyl biphenyl fluorine-containing compound | 山东盛华新材料科技股份有限公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-108341774-A | Substituted quinolinones inhibitor | 北京赛林泰医药技术有限公司 | 2018-07-31 | — | — | CN | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
| US-9517990-B2 | Negative dielectric anisotropic liquid crystal compounds containing 2,3-difluorophenyl group, and preparation method and use thereof | Shijiazhuang Chenzhi Yonghua Display Materials Co., Ltd. (CN) | 2016-12-13 | — | — | US | disclosed |
| US-9517990-B2 | Negative dielectric anisotropic liquid crystal compounds containing 2,3-difluorophenyl group, and preparation method and use thereof | Shijiazhuang Chenzhi Yonghua Display Materials Co., Ltd. (CN) | 2016-12-13 | — | — | US | disclosed |
| US-9517990-B2 | Negative dielectric anisotropic liquid crystal compounds containing 2,3-difluorophenyl group, and preparation method and use thereof | Shijiazhuang Chenzhi Yonghua Display Materials Co., Ltd. (CN) | 2016-12-13 | — | — | US | disclosed |
| US-9428693-B2 | Liquid crystal composition having negative dielectric anisotropy | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO., LTD. (CN) | 2016-08-30 | — | — | US | disclosed |
| US-9428693-B2 | Liquid crystal composition having negative dielectric anisotropy | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO., LTD. (CN) | 2016-08-30 | — | — | US | disclosed |
| US-9303208-B2 | Liquid crystal compound containing cyclopentyl and difluorometheneoxy linking group, preparation method and application thereof | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO., LTD. (CN) | 2016-04-05 | — | — | US | disclosed |
| US-9303208-B2 | Liquid crystal compound containing cyclopentyl and difluorometheneoxy linking group, preparation method and application thereof | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO., LTD. (CN) | 2016-04-05 | — | — | US | disclosed |
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080287695-A1 | Agent For Optical Resolution, Process For Producing Optically Active Substance and 1,5-Substituted Bicyclo [3.3.0] -2-Oxaoctane Compound | ZEON CORPORATION (JP) | 2008-11-20 | — | — | US | disclosed |
| US-20080287695-A1 | Agent For Optical Resolution, Process For Producing Optically Active Substance and 1,5-Substituted Bicyclo [3.3.0] -2-Oxaoctane Compound | ZEON CORPORATION (JP) | 2008-11-20 | — | — | US | disclosed |
| US-20080287695-A1 | Agent For Optical Resolution, Process For Producing Optically Active Substance and 1,5-Substituted Bicyclo [3.3.0] -2-Oxaoctane Compound | ZEON CORPORATION (JP) | 2008-11-20 | — | — | US | disclosed |
| EP-1984340-A1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. | 2007-09-20 | — | — | US | disclosed |
| US-7259183-B2 | Indole, indazole and indoline derivatives as CETP inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| WO-2007090752-A1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| EP-1719746-A1 | OPTICAL RESOLVER, PROCESS FOR PRODUCING OPTICALLY ACTIVE ISOMER, AND 1,5-SUBSTITUTED BICYCLO (3.3.0) -2-OXAOCTANE COMPOUND | ZEON CORPORATION (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | HTR2C 521/4885ACMSD 3435/4885KCNH2 2376/4885 |
| US-20080287695-A1 | Agent For Optical Resolution, Process For Producing Optically Active Substance and 1,5-Substituted Bicyclo [3.3.0] -2-Oxaoctane Compound | ALDH1A2, OXER1, HCRTR1 | HTR2C 1114/4885ACMSD 169/4885KCNH2 1430/4885 |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | AADAT, AAAS, AADAC | HTR2C 85/4885ACMSD 4/4885KCNH2 1568/4885 |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | HTR2C 1857/4885ACMSD 2880/4885KCNH2 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.